avasimibe has been researched along with Arteriosclerosis in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 6 (85.71) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Burnett, JR; Huff, MW | 1 |
| Miyazaki, A; Watanabe, T | 1 |
| Krause, BR; Nicolosi, RJ; Wilson, TA | 1 |
| Bocan, TM; Dagle, C; Krause, BR; Lathia, C; Lee, H; Lu, X; Major, T; Mueller, SB; Rosebury, WS | 1 |
| Breider, MA; Milad, MA; Robertson, DG | 1 |
| de Wit, EC; Delsing, DJ; Gijbels, MJ; Havekes, LM; Jukema, JW; Offerman, EH; Princen, HM; van Der Boom, H; van Der Laarse, A; van Duyvenvoorde, W | 1 |
| Auerbach, B; Bak Mueller, S; Bocan, TM; Dagle, C; Krause, BR; Lu, X; Rosebury, WS; Sliskovic, DR | 1 |
2 review(s) available for avasimibe and Arteriosclerosis
| Article | Year |
|---|---|
Avasimibe Pfizer.
Topics: Acetamides; Acetates; Animals; Arteriosclerosis; Clinical Trials as Topic; Drug Industry; Enzyme Inhibitors; Humans; Hyperlipidemias; Sulfonamides; Sulfonic Acids | 2002 |
[Acyl-coenzyme A: cholesterol acyltransferase (ACAT)].
Topics: Acetamides; Acetates; Adiponectin; Animals; Arteriosclerosis; Cholesterol Esters; Disease Models, Animal; Drug Design; Foam Cells; Humans; Intercellular Signaling Peptides and Proteins; Sterol O-Acyltransferase; Sterol O-Acyltransferase 2; Sulfonamides; Sulfonic Acids | 2004 |
5 other study(ies) available for avasimibe and Arteriosclerosis
| Article | Year |
|---|---|
The ACAT inhibitor, CI-1011 is effective in the prevention and regression of aortic fatty streak area in hamsters.
Topics: Acetamides; Acetates; Animals; Aorta; Arteriosclerosis; Cholesterol; Cholesterol Esters; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Cricetinae; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Enzyme Inhibitors; Liver; Male; Reference Values; Sterol O-Acyltransferase; Sulfonamides; Sulfonic Acids; Time Factors; Triglycerides | 1998 |
The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits.
Topics: Acetamides; Acetates; Animals; Anticholesteremic Agents; Aorta, Thoracic; Arteriosclerosis; Base Sequence; Cholesterol; DNA Primers; Enzyme Inhibitors; Gene Expression; Humans; Hypercholesterolemia; Macrophages; Male; Matrix Metalloproteinases; Rabbits; Sterol O-Acyltransferase; Sulfonamides; Sulfonic Acids; Tissue Inhibitor of Metalloproteinases | 2000 |
Preclinical safety evaluation of avasimibe in beagle dogs: an ACAT inhibitor with minimal adrenal effects.
Topics: Acetamides; Acetates; Administration, Oral; Adrenal Glands; Alanine Transaminase; Animals; Area Under Curve; Arteriosclerosis; Cholesterol; Cytochrome P-450 Enzyme System; Dogs; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Enzyme Inhibitors; Erythrocytes; Female; Hypolipidemic Agents; Liver; Longevity; Male; Microsomes, Liver; Sterol O-Acyltransferase; Sulfonamides; Sulfonic Acids; Toxicity Tests | 2001 |
Acyl-CoA:cholesterol acyltransferase inhibitor avasimibe reduces atherosclerosis in addition to its cholesterol-lowering effect in ApoE*3-Leiden mice.
Topics: Acetamides; Acetates; Animals; Anticholesteremic Agents; Aortic Valve; Apolipoprotein E3; Apolipoproteins E; Arteriosclerosis; Body Weight; Cell Adhesion; Cell Line; Cholesterol; Diet, Atherogenic; Disease Models, Animal; Eating; Endothelium, Vascular; Female; Heterozygote; Lipoproteins; Macrophages; Mice; Mice, Transgenic; Sterol O-Acyltransferase; Sulfonamides; Sulfonic Acids | 2001 |
The combined effect of inhibiting both ACAT and HMG-CoA reductase may directly induce atherosclerotic lesion regression.
Topics: Acetamides; Acetates; Animals; Arteriosclerosis; Coenzyme A-Transferases; Drug Therapy, Combination; Hydroxymethylglutaryl CoA Reductases; Hypolipidemic Agents; Rabbits; Simvastatin; Sulfonamides; Sulfonic Acids | 2001 |